Antigen Detection


  • Test Code


  • Clinical Significance

    The aspergillus EIA test aids in the early diagnosis of invasive aspergillosis. In conjunction with other diagnostic tests and clinical signs of disease it is an aid in the effective early treatment of disease.

  • Methodology

    Platelia™ Aspergillus EIA immunoenzymatic sandwich microplate assay, cleared by the FDA for the detection of galactomannan in serum or BALF.

  • Limitations

    The result is not intended to be used as the sole means for clinical diagnosis or patient management decisions.

    • Antifungal therapy may cause false negative results in patients with aspergillosis.

    False positives can be caused by:

    • Piperacillin-tazobactam, amoxicillin/clavulanic acid
    • PLASMA-LYTE and other fluids containing sodium gluconate
    • Infection with Penicillium, Alternaria, Paecilomyces, Fusarium, Histoplasma and Blastomyces, or airway colonization with above organisms.
  • Specimen Collection
    • Serum: Collect serum specimens in serum separator or red top tube. Allow blood to clot for 30 minutes, then centrifuge. Pipette serum into a plastic screw cap vial.
    • Urine/CSF/BAL: Submit CSF and BAL in a sterile screw cap container.
  • Minimum Specimen Requirements

    Serum/Urine/CSF/BAL: 0.8 mL

  • Specimen Stability
    • Room Temperature: 48 hours
    • Refrigerated: 5 days
    • Frozen: 5 months
  • Specimen Rejection

    If specimen is too viscous to pipette.

  • Transport Temperature


  • Shipping

    Ship on dry ice or frozen packs for next day service. Monday-Friday delivery

  • Turnaround Time

    Serum/CSF/BAL: Same day

    *New positives may require confirmation

  • Reference Range


  • Interpretative Information
    • Negative: <0.5

    *Results are reported as numeric values (Index) which are interpreted as positive or negative.

  • Additional Information

    Platelia™ is a registered trademark of BioRad.

  • vendor logo
  • vendor logo
  • vendor logo
  • vendor logo
  • vendor logo